STAT
STAT's Pharmalittle notes Catherine Hanaway says Lilly broke its promise on discounted drugs to hospitals, alongside new results for a Lilly weight loss drug.
Recap by typeshit. Full story at STAT.
STAT
The temporary enforcement discretion covers six peptides an FDA advisory committee recommended in July. STAT notes there is little evidence for many of these wellness compounds.
A US judge turned down Novo's request to halt Lilly's Zepbound advertising while the false advertising dispute continues.
STAT notes RFK Jr. and the MAHA movement have embraced peptides, though evidence for many of these wellness compounds is thin. A July FDA panel backed all six.
AP reports agency scientists did not back the administration's effort to loosen rules on peptide drugs that remain unproven.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
Zhavoronkov quotes a speaker calling Mounjaro one of the best molecules humans have made, alongside Novo's semaglutide data at the aging conference.
Loading…